Crown Reserve Acquisition Corp. I Reports $263K Net Loss, Enters Merger Agreement with Carvix, Inc.

Crown Reserve Acquisition Corp. I reported a net loss of $263,493 for the three months ended March 31, 2026, compared to a net loss of $1,373,163 for the previous fiscal period. The company incurred general and administrative costs of $68,837 and professional fees of $115,000 during this quarter. A significant factor contributing to the loss was a $1,604,397 decrease in the fair value of warrant liabilities, which was partially offset by $1,524,741 in dividends earned on marketable securities held in the Trust Account. The total assets of the company increased to $175.2 million as of March 31, 2026, up from $173.9 million at the end of the previous fiscal year.

In terms of operational changes, Crown Reserve Acquisition Corp. I has made significant strides in its strategic direction by entering into a Business Combination Agreement with Carvix, Inc. on March 30, 2026. This agreement outlines plans for a merger, which will involve a domestication to Delaware and the merger of a wholly owned subsidiary with Carvix. The company aims to complete this transaction by September 30, 2026, with the potential for an extension to February 10, 2027, if necessary. The merger is expected to enhance the company’s market position and operational capabilities.

As of March 31, 2026, the company had 18,056,250 Class A and Class B ordinary shares issued and outstanding, with 17,250,000 Class A shares subject to possible redemption at a value of $10.00 per share. The Trust Account held $174.9 million, reflecting a slight increase from the previous quarter. The company’s working capital deficit was funded entirely by the Sponsor, with a receivable of $210,670 due from the Sponsor as of the end of the quarter. The company has no cash outside the Trust Account and is reliant on the Sponsor for operational funding.

Looking ahead, Crown Reserve Acquisition Corp. I faces challenges related to its ability to complete the Business Combination with Carvix. The company has indicated that if the merger does not occur by the Outside Date, it will be required to cease operations and liquidate. Management has expressed confidence in the potential for the merger to proceed, but acknowledges the risks associated with meeting the necessary conditions for completion. The company continues to monitor its financial position closely, particularly in light of its reliance on external funding and the need for additional financing to support its operations and transaction costs.